PlainPharmaWatch

CMS Open Payments · Program Year 2024

Braintree Laboratories, Inc.

Braintree Laboratories, Inc. reported $33,946,527.64 across General Payments, Research, and Ownership to 5,369 physicians and teaching hospitals across 8,836 transactions.

See the rankings → How this is sourced
$33.9M Top 10% payer
All-tracks total
8,836 Top quartile volume
Transactions
5,369 Top quartile reach
Recipients
−$88.9K
General Payments vs PY2023

Braintree Laboratories, Inc. reported $33,946,527.64 across all CMS Open Payments tracks (General + Research + Ownership) to 5,369 physicians and teaching hospitals in Program Year 2024 - ranking #63 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $652,028.36, averaging $6.3K per recipient.

How Braintree Laboratories, Inc.'s $33.9M all-tracks total breaks down

Braintree Laboratories, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

C

76/100

Total payments

A

100/100

Transaction volume

C

74/100

Physician reach

D

51/100

Payment type diversity

C

77/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer braintree-laboratories-inc Braintree Laboratories, Inc.

$33.9M · #63/1,925 · 0.2% industry · PY2024

  • TOT $33.9M
  • RANK #63
  • SHARE 0.2%
  • TXN 8,836
  • RCP 5,369
  • CAT 6
  • GEN $652.0K
  • ΔGEN −$88.9K
  • TOP1 34.4%
  • PY 2024

Volume peers

Nearest volume peer: Kite Pharma, Inc. ($34.1M)

Alexion Pharmaceuticals, Inc.$34.7MKite Pharma, Inc.$34.1MBraintree Laboratories, Inc.…$33.9MMirati Therapeutics, Inc.$33.7MSN Holdings, LLC$32.8M
All-tracks payment totals near Braintree Laboratories, Inc. (CMS Open Payments PY2024)

Braintree Laboratories, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Braintree Laboratories, Inc.'s CMS-reported General Payments decreased by $88.9K (−12.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BRAINTREE LABORATORIES, INC.PY2023: BRAINTREE LABORATORIES, INC.PY2024: Braintree Laboratories, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$740.9KPY2024$652.0K
PY2023
$740,931.65
PY2024
$652,028.36

What the Data Shows for Braintree Laboratories, Inc.

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Braintree Laboratories, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $382.1K, accounting for 58.6% of this company's General Payments and 12 transactions.

General Payment Breakdown by Type

Braintree Laboratories, Inc. made 6 types of general payments. "Royalty or License" is the largest category at $382.1K, 58.6% of General Payments.

Braintree Laboratories, Inc. reports 6 general-payment categories - the top three are Royalty or License (58.6%), Consulting Fee (22.2%), and Food and Beverage (16.3%). The remaining 3 categories make up 2.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Braintree Laboratories, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Royalty or License$382.1K2. Consulting Fee$144.9K3. Food and Beverage$106.6K4. Gift$12.9K5. Grant$5.5K6. Education$80.85
Payment Type Amount Transactions
Royalty or License $382.1K 12
Consulting Fee $144.9K 21
Food and Beverage $106.6K 5,140
Gift $12.9K 178
Grant $5.5K 3
Education $80.85 15

Recipient Concentration in General Payments

The five largest recipient relationships account for $515,137.03 (79.0%) of $652,028.36 in this company's General Payments records across 3,621 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Braintree Laboratories, Inc.

The five named recipients with the highest reported General Payments from this company

John Fordtran$224.2KGlenn Davis$157.9KJack Dipalma$124.0KFrancis Farraye$5.0KDaniel John Pambianco$4.0K
  1. 1

    John Fordtran

    $224,157.00 across 8 reported transactions

  2. 2

    Glenn Davis

    $157,911.49 across 4 reported transactions

  3. 3

    Jack Dipalma

    $124,029.21 across 12 reported transactions

  4. 4

    Francis Farraye

    $5,000.00 across 1 reported transactions

  5. 5

    Daniel John Pambianco

    $4,039.33 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Braintree Laboratories, Inc. ranks #63 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #728 of 1,838 by HHI (top 40% most concentrated), a wider distribution than most similarly sized payers.

00.30.50.81.12095.22116.32137.52158.72179.8Total payments ($M)Concentration (HHI, 0-10,000)
Braintree Laboratories, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Braintree Laboratories, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Braintree Laboratories, Inc..

elliquence, LLC

HHI 2127

Route 92 Medical, Inc.

HHI 2140

Allerderm Laboratories

HHI 2140

Embecta Corp.

HHI 2146

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Braintree Laboratories, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Braintree Laboratories, Inc. ranks #63 of 1,925 by all-tracks total payments, led by "Royalty or License".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Braintree Laboratories, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.